Post by icemandios on Nov 7, 2023 13:55:43 GMT
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
PR Newswire
World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country
BOSTON and ELMWOOD PARK, N.J. and ROLLE, Switzerland , Nov. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference ® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.
Since January 2023 , Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS have been working on merging MSK-ACCESS® technology with the SOPHiA DDM™ platform algorithms to provide a comprehensive liquid biopsy assay available on the decentralized platform. The new offering takes advantage of the sophisticated analytics of the SOPHiA DDM™ platform, combining its state-of-the-art algorithms and global network with the scientific and clinical expertise of MSK in cancer genomics. The onboarding of BioReference aims to bring access to world-class liquid biopsy testing to the laboratory's customers across the country.
"The availability of MSK-ACCESS® powered with SOPHiA DDM ™ will support pioneer laboratories like BioReference take their genomic analysis capabilities to the next level, by enhancing their ability to serve their customers with a cutting-edge liquid biopsy assay," said Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS . "We are eager to begin implementation with BioReference and help bring this critical cancer testing technology to more areas throughout the U.S., including rural and underserved populations."
BioReference currently operates 10 laboratory facilities across the U.S. and provides scientific expertise in oncology, urology, and women's health. The laboratory's oncology division, GenPath Oncology, offers a comprehensive portfolio to support the continuum of care of cancer patients – from risk assessment to treatment planning. Deploying in-house liquid biopsy testing will enable the laboratory to analyze samples from a simple, non-invasive blood draw, allowing for less invasive monitoring of cancers. The offering will incorporate SOPHiA GENETICS' advanced genomic analysis, made possible with artificial intelligence (AI), and expedited streamlined insights to increase the ability of clinician researchers to practice precision medicine.
"We're proud to be the first commercial laboratory to be able to offer this liquid-based technology," Ellen Beausang , Chief Commercial Officer, BioReference Health, LLC. "The adoption of the SOPHiA GENETICS platform along with MSK's oncology genomics technology signals our ongoing and unwavering commitment to improving cancer care for patients, and offering advanced tools and solutions that empower timely and critical decision-making for healthcare providers and patient outcomes."
MSK-ACCESS® powered with SOPHiA DDM™ is being designed to align with the most up-to-date guidelines and clinical trial data, reflecting major biologically actionable biomarkers. In addition to quickly providing analysis and insights, the SOPHiA DDM™ Platform will allow BioReference to retain ownership of its database and obtain reproducible data that can help accelerate future work.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X (formerly known as Twitter), LinkedIn , Facebook , and Instagram .
For more information on BioReference, visit www.bioreference.com/ , or connect on LinkedIn , Instagram , Facebook and X .
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM , or connect on X (formerly known as Twitter), LinkedIn , Facebook , and Instagram . Where others see data, we see answers.
About BioReference Health, LLC
BioReference® Health LLC, an OPKO Health, Inc. Company (NASDAQ: OPK), empowers confident healthcare decisions by prioritizing service, creating innovative solutions, and offering scientific expertise in oncology, urology, and women's health. Headquartered in Elmwood Park, New Jersey , BioReference operates 10 laboratory facilities around the country, is in-network with the largest health plans in the United States and processes more than 12 million tests annually. BioReference provides credible and tailored solutions for a variety of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, government agencies, educational systems, and sport leagues. In addition to an extensive test menu with 99 percent of tests performed in-house, BioReference's differentiated offerings include large-scale health screening programs, on-demand mobile phlebotomy, and transformative business solutions that optimize laboratory management. For more information visit www.bioreference.com/ .
MSK-ACCESS® powered with SOPHiA DDM™ is a product in development and may not be available for sale. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
PR Newswire
World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country
BOSTON and ELMWOOD PARK, N.J. and ROLLE, Switzerland , Nov. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference ® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.
Since January 2023 , Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS have been working on merging MSK-ACCESS® technology with the SOPHiA DDM™ platform algorithms to provide a comprehensive liquid biopsy assay available on the decentralized platform. The new offering takes advantage of the sophisticated analytics of the SOPHiA DDM™ platform, combining its state-of-the-art algorithms and global network with the scientific and clinical expertise of MSK in cancer genomics. The onboarding of BioReference aims to bring access to world-class liquid biopsy testing to the laboratory's customers across the country.
"The availability of MSK-ACCESS® powered with SOPHiA DDM ™ will support pioneer laboratories like BioReference take their genomic analysis capabilities to the next level, by enhancing their ability to serve their customers with a cutting-edge liquid biopsy assay," said Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS . "We are eager to begin implementation with BioReference and help bring this critical cancer testing technology to more areas throughout the U.S., including rural and underserved populations."
BioReference currently operates 10 laboratory facilities across the U.S. and provides scientific expertise in oncology, urology, and women's health. The laboratory's oncology division, GenPath Oncology, offers a comprehensive portfolio to support the continuum of care of cancer patients – from risk assessment to treatment planning. Deploying in-house liquid biopsy testing will enable the laboratory to analyze samples from a simple, non-invasive blood draw, allowing for less invasive monitoring of cancers. The offering will incorporate SOPHiA GENETICS' advanced genomic analysis, made possible with artificial intelligence (AI), and expedited streamlined insights to increase the ability of clinician researchers to practice precision medicine.
"We're proud to be the first commercial laboratory to be able to offer this liquid-based technology," Ellen Beausang , Chief Commercial Officer, BioReference Health, LLC. "The adoption of the SOPHiA GENETICS platform along with MSK's oncology genomics technology signals our ongoing and unwavering commitment to improving cancer care for patients, and offering advanced tools and solutions that empower timely and critical decision-making for healthcare providers and patient outcomes."
MSK-ACCESS® powered with SOPHiA DDM™ is being designed to align with the most up-to-date guidelines and clinical trial data, reflecting major biologically actionable biomarkers. In addition to quickly providing analysis and insights, the SOPHiA DDM™ Platform will allow BioReference to retain ownership of its database and obtain reproducible data that can help accelerate future work.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X (formerly known as Twitter), LinkedIn , Facebook , and Instagram .
For more information on BioReference, visit www.bioreference.com/ , or connect on LinkedIn , Instagram , Facebook and X .
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM , or connect on X (formerly known as Twitter), LinkedIn , Facebook , and Instagram . Where others see data, we see answers.
About BioReference Health, LLC
BioReference® Health LLC, an OPKO Health, Inc. Company (NASDAQ: OPK), empowers confident healthcare decisions by prioritizing service, creating innovative solutions, and offering scientific expertise in oncology, urology, and women's health. Headquartered in Elmwood Park, New Jersey , BioReference operates 10 laboratory facilities around the country, is in-network with the largest health plans in the United States and processes more than 12 million tests annually. BioReference provides credible and tailored solutions for a variety of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, government agencies, educational systems, and sport leagues. In addition to an extensive test menu with 99 percent of tests performed in-house, BioReference's differentiated offerings include large-scale health screening programs, on-demand mobile phlebotomy, and transformative business solutions that optimize laboratory management. For more information visit www.bioreference.com/ .
MSK-ACCESS® powered with SOPHiA DDM™ is a product in development and may not be available for sale. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.